Innovative solutions to
keep your project on course

Regulatory Affairs

Nuventra’s approach to regulatory affairs is to match regulatory expertise with scientific, clinical, nonclinical, and overall drug development expertise to support marketing approval and market acceptance.

While a key understanding of the FDA regulations, guidance documents, and procedural techniques (e.g., the proper eCTD publishing format) is important, it is equally as important to be able to summarize a well-written but succinct argument to the FDA grounded in proven scientific, clinical, nonclinical, CMC, and overall drug development strategies and principals that support the overall strategic message to the regulatory authorities.

Nuventra brings these qualities to your program as we look critically and strategically at all drug development activities supporting regulatory interactions.

FDA Meetings

Successful interactions with regulatory authorities are a critical component to a successful drug development program. We believe that this can be best achieved by a realistic strategic assessment of the strengths and weaknesses of each individual program.  In addition to our efforts “behind the scenes” of various submissions, we regularly attend meetings with the FDA for our clients (e.g., Pre-IND, end of Phase 1 [EoP1], end of Phase 2 [EoP2], pre-NDA, pre-BLA, and Type C meetings), with our consultants having participated in more than 100 such meetings involving diverse product classes and therapeutic areas. Through these interactions, we have developed a keen understanding of current attitudes at the FDA, especially regarding clinical pharmacology and pharmacokinetics, but more broadly as well. Using this experience, we are able to determine issues of critical importance to the FDA and advise our clients on appropriate strategies to meet the challenges they face.

As part of our interactions with the FDA, our consultants have participated in teleconferences, face-to-face meetings, and written correspondence with FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) across multiple divisions and offices, including the Divisions of Anesthesia, Analgesia, and Addiction Products (DAAAP), Cardiovascular and Renal Drug Products (DCaRP), Gastroenterology and Inborn Errors Products (DGIEP), Metabolism and Endocrinology Products (DMEP), Neurology Products (DNP), Nonprescription Drug Products (DNDP), and Pulmonary, Allergy, and Rheumatology Products (DPARP) and the Offices of Cellular, Tissue and Gene Therapies (OCTGT), Hematology and Oncology Drug Products (OHOP), and Orphan Products Development (OOPD).

eCTD Publishing

In addition to our writing and consulting services, we also offer full-service, electronic Common Technical Document (eCTD) submission support for our clients. Through this service, we compile and organize a client’s submission using a standardized submission management software solution, perform quality checks on each constituent document to ensure compliance with established electronic document standards, validate the combined submission, and upload the validated submission to FDA’s Electronic Submissions Gateway (ESG).

Regulatory Services

  • CTD / eCTD Modules 1 to 5
    • Module 1 Administrative Information
    • Module 2 Summaries
      • Especially 2.4 Nonclinical Overview, 2.5 Clinical Overview, 2.6 Nonclinical Written and Tabulated Summaries, 2.7 Clinical Summary (2.7.1 and 2.7.2 Biopharmaceutics and Pharmacology),
    • Module 3 Quality
    • Module 4 Nonclinical Study Reports
    • Module 5 Clinical Study Reports
  • FDA / EMA / PMDA Meetings
    • Full meeting management and attendance
    • Briefing document preparation
  • Attend FDA / EMA / PMDA meetings as a subject matter (SME) expert (clinical pharmacology/PK, toxicology, medical, regulatory, biostats expert representation at regulatory meetings)
  • Investigator Brochure authoring and updates
  • IND annual reports
  • Clinical trial protocols and Clinical Study Reports (CSRs)
  • Full electronic eCTD publishing services
  • IND/NDA/BLA submissions (all modules)
  • Orphan drug applications
  • Drug naming applications (nonproprietary and proprietary)
  • Pediatric Study Plans (PSPs) and Pediatric Investigational Plans (PIPs)
  • Investigational Medicinal Product Dossiers (IMPD) and other international regulatory documents
  • Other regulatory forms and applications

Explore Our Blog

Lessons from FDA’s Grand Rounds: “How Simulation Can Transform Regulatory Pathways”

Modeling and simulation are transforming how drugs are developed and how they are regulated. This is the conclusion from a…

Read More
3 Pathways to Approval

Abbreviated New Drug Application vs. 505(b)(2) NDA: Choosing the Right Path

by Scientific Writing Team  Media attention and investor fanfare in drug development tend to focus on novel therapies. But did you…

Read More
Questions for the FDA

Former FDA Reviewers Provide Answers to Key Questions

Nuventra’s consultants Gene Williams and Brian Furmanski spent a combined 23 years working for the FDA. In this new blog…

Read More